What is the dose rate in millisieverts per hour at 1 meter from a 10 mCi (≈370 MBq) fluorine‑18 (^18F) source?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Dose Rate Calculation for 10 mCi F-18 at 1 Metre

At 1 metre from a 10 mCi (370 MBq) F-18 source, the dose rate is approximately 0.06 mSv/hour (60 µSv/hour).

Calculation Methodology

The dose rate can be calculated using the gamma factor (dose rate constant) for F-18, which has been experimentally validated in recent research:

  • Gamma factor for F-18 at 1 metre: 0.161 µSv/h/MBq 1
  • For 370 MBq (10 mCi): 0.161 × 370 = 59.6 µSv/h ≈ 0.06 mSv/h

This calculation assumes a point source geometry in air without attenuation.

Clinical Context and Self-Attenuation

When F-18 is administered to a patient (rather than as an isolated source), self-attenuation reduces the external dose rate by approximately 29% 1. The average self-attenuation factor for F-18 in patients is 0.71 ± 0.04, meaning:

  • Patient dose rate at 1 metre: approximately 0.04 mSv/h (40 µSv/h) for 370 MBq administered activity

This represents a more realistic clinical scenario where the radioactivity is distributed within body tissues.

Distance and Shielding Considerations

Distance is more effective than lead shielding for F-18 radiation protection 2:

  • Dose rate follows inverse square law in air
  • At 2 metres from a 370 MBq source, dose rate drops to <20 µGy/h (below unrestricted area limits)
  • Lead shielding (0.318 cm thick) only reduces dose to ~60% of unshielded values due to scattered photons and characteristic x-rays
  • A 33% increase in distance provides equivalent protection to 0.318 cm lead shielding 2

Practical Implications

For radiation safety planning with F-18 sources or patients:

  • Maintain 2+ metre distance when possible rather than relying on lead barriers
  • The effective dose coefficient for F-18-FDG is 1.9×10⁻² mSv/MBq (0.019 mSv/MBq) for internal patient dosimetry 3
  • External dose rates decrease rapidly with time due to F-18's 110-minute half-life

References

2
Research

18F protection issues: human and gamma-camera considerations.

Journal of nuclear medicine technology, 2003

Related Questions

What are the exact radiation exposure (dose‑rate) values at 1 m for therapeutic (¹³¹I, ⁹⁰Y, ¹⁷⁷Lu) and diagnostic (¹⁸F‑FDG, ⁹⁹mTc, ¹²³I, ¹¹¹In) nuclear‑medicine procedures?
In an FDG PET-CT study, what does it indicate when a focus of increased FDG uptake is seen on both the non‑attenuation‑corrected (NAC) and attenuation‑corrected (AC) images?
What are the recommended imaging acquisition parameters for an F‑18 DOPA PET scan, including timing, reconstruction, reference region, and patient preparation?
Is it appropriate to give loratadine 4 mg at night, cetirizine 10 mg twice daily, and prednisolone 5 mg three times daily?
What note statement should I use to indicate the patient should continue glucose‑dependent medication therapy (Gdmt) without interruption?
What probiotic is recommended for an 18‑month‑old child?
In a healthy 30‑year‑old male not on anticoagulants and without prior brain pathology, does a minor head impact against a plastic dryer door pose a risk of intracranial hemorrhage?
Is it safe to drink alcohol while taking Lexapro (escitalopram) and hydroxyzine?
What is the difference between occlusive deep vein thrombosis and non‑occlusive deep vein thrombosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.